James L Reid

US Patent:

6404445, Jun 11, 2002

Filed:

Dec 30, 1999

Appl. No.:

09/475769

Inventors:

Jeffrey Thomas Galea - Fremont CA
Noah Christopher Woodman - Santa Clara CA
James Richard Reid - San Jose CA
James Malcolm Sprinkle - San Jose CA

Assignee:

Cybrant Corporation - Mountain View CA

International Classification:

G06F 300

US Classification:

345853, 345762, 345744, 345733, 345764, 707513, 707515, 709201, 709203

Abstract:

A method and system for processing data are described. In one embodiment, a constraint-based configuration file is generated from a pre-defined data configuration domain at a server. In addition, the constraint-based configuration file is mapped into a plurality of display pages at a client, and a page of the plurality of display pages is updated directly from the constraint-based configuration file.

US Patent:

7790669, Sep 7, 2010

Filed:

Aug 4, 1998

Appl. No.:

09/129028

Inventors:

James Steven Reid - Berkeley CA, US
James H. Fallon - Irvine CA, US

Assignee:

Neurorepair, Inc. - San Francisco CA

International Classification:

A61K 38/00
A61K 49/00
C12N 5/00
C12N 5/07
C12N 5/079
C12N 5/0793
C12N 5/0797
C07K 14/00

US Classification:

514 2, 424 91, 435368, 435366, 435326, 435336, 530350

Abstract:

The present invention features methods and compositions for treating a patient who has a neurological deficit. The method can be carried out, for example, by contacting (in vivo or in culture) a neural progenitor cell of the patient's central nervous system (CNS) with a polypeptide that binds the epidermal growth factor (EGF) receptor and directing progeny of the proliferating progenitor cells to migrate en masse to a region of the CNS in which they will reside and function in a manner sufficient to reduce the neurological deficit. The method may include a further step in which the progeny of the neural precursor cells are contacted with a compound that stimulates differentiation.

US Patent:

8158578, Apr 17, 2012

Filed:

Aug 26, 2010

Appl. No.:

12/869468

Inventors:

James Steven Reid - Berkeley CA, US
James H. Fallon - Irvine CA, US

Assignee:

Neurorepair, Inc. - San Francisco CA

International Classification:

A61K 38/00
A61K 49/00
A61K 38/18
A61B 5/00
C07K 14/475
C07K 14/48

US Classification:

514 11, 514 12, 514 13, 514 76, 514 83, 514 84

Abstract:

The present invention features methods and compositions for treating a patient who has a neurological deficit. The method can be carried out, for example, by contacting (in vivo or in culture) a neural progenitor cell of the patient's central nervous system (CNS) with a polypeptide that binds the epidermal growth factor (EGF) receptor and directing progeny of the proliferating progenitor cells to migrate en masse to a region of the CNS in which they will reside and function in a manner sufficient to reduce the neurological deficit. The method may include a further step in which the progeny of the neural precursor cells are contacted with a compound that stimulates differentiation.

US Patent:

20010007657, Jul 12, 2001

Filed:

Dec 18, 2000

Appl. No.:

09/739933

Inventors:

James Reid - Berkeley CA, US
James Fallon - Irvine CA, US

International Classification:

A01N063/00

US Classification:

424/093700

Abstract:

The invention provides compositions and methods for attracting glial and neuronal progenitor cells and their progeny to desired sites within the central nervous system tissue. These compositions and methods can also be used to induce directed differentiation of these cells. By providing various ways to generate new glial and neuronal cells from endogenous progenitor cells, the invention also provides methods for inducing regeneration of tissues and neurological function, and, indeed, generating new phenotypes and capabilities. Thus, the invention features methods and compositions for ameliorating neurological deficits, including inherited disorders, trauma, infections and the like.

US Patent:

20020004039, Jan 10, 2002

Filed:

Jul 31, 2001

Appl. No.:

09/920085

Inventors:

James Reid - Berkeley CA, US
James Fallon - Irvine CA, US

Assignee:

The Regents of the University of California, a California corporation

International Classification:

A61K045/00
C12N005/08

US Classification:

424/093700, 435/368000

Abstract:

The present invention features methods and compositions for treating a patient who has a neurological deficit. The method can be carried out, for example, by contacting (in vivo or in culture) a neural progenitor cell of the patient's central nervous system (CNS) with a polypeptide that binds the epidermal growth factor (EGF) receptor and directing progeny of the proliferating progenitor cells to migrate en masse to a region of the CNS in which they will reside and function in a manner sufficient to reduce the neurological deficit. The method may include a further step in which the progeny of the neural precursor cells are contacted with a compound that stimulates differentiation.

US Patent:

20180177464, Jun 28, 2018

Filed:

May 19, 2015

Appl. No.:

14/715793

Inventors:

- Mountain View CA, US
James Moad Reid - Mountain View CA, US
Jeffrey L. Rogers - San Carlos CA, US

International Classification:

A61B 5/00
A61B 5/021
A61B 5/107
A61B 5/0205

Abstract:

This document describes optical central venous pressure measurement. To determine the central venous pressure (CVP) of a person optically, video of a right side of the person's neck is captured. By way of example, a medical professional records a video of the right side of the person's neck using a smartphone. The right side of the person's neck is captured because it is where the person's external and internal jugular veins are located and pulsatile motions that are usable to measure CVP occur in those veins. The video is then processed according to video motion amplification techniques to generate a reconstructed video of the right side of the person's neck. In the reconstructed video, the pulsatile motion of the person's venous system that occurs at the right side of their neck is visually amplified. Using the reconstructed video, measurements are made of a distance between a peak of the visually-amplified pulsatile motion and an anatomical feature of the person. The measured distance between the peak of the visually-amplified pulsatile motion and the anatomical feature is used to determine CVP of the person. These techniques enable CVP to be determined without relying on estimates made by medical professionals.